Balstilimab

Monoclonal antibody

Also known as AGEN2034

Stoppedregistry status

Evidence outlook

Phase 3 study withdrawn before enrolling; a study outside Cervical Cancer is active

The furthest-phase study registered for this program (NCT04943627) was withdrawn before enrolling, and no Cervical Cancer study is active; a study outside Cervical Cancer is active on the registry. No evidence signal is assigned from a stopped study. Check the registry record for the sponsor's stated reason.

Latest reported trial: NCT03104699 · Phase 1/2 · met primary endpoint · grade pending

Also in development:Non-Small Cell Lung Cancer · Phase 2

Featured evidence outside this drug's tracked markets:CIME (NCT06346197) · Gastric Cancer · Phase 3 · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Cervical Cancer
NCT04943627 · Agenus Inc.
2021-08-02 – 2021-10-22 · Advanced Cancer, Metastatic Cervical Cancer
What this study did
Other / comorbidity
NCT06346197 · Centre Leon Berard
2025-12-08 – 2028-05-15 · Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer
What this study did
NCT07152821 · Canadian Cancer Trials Group
2026-03-31 – 2026-07-13 · Colorectal Cancer
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06279130 · The Netherlands Cancer Institute
2024-01-29 – 2034-01-29 · Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors
What this study did
Phase 2 (30)
Cervical Cancer
NCT05033132 · Agenus Inc.
2021-10-01 – 2024-12-30 · Cervical Cancer
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07735624 · Dana-Farber Cancer Institute
2026-08-10 – 2032-12-31 · Early Rectal Cancer, Stage I Rectal Cancer, Microsatellite Stable Rectal Carcinoma
What this study did
NCT05864534 · Northwestern University
2024-01-19 – 2031-08-31 · Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme
What this study did
NCT07227636 · Memorial Sloan Kettering Cancer Center
2025-11-07 – 2030-11 · Colorectal Cancer, Rectal Cancer
What this study did
NCT06843551 · Benjamin Spieler
2025-06-18 – 2030-08-01 · Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
What this study did
NCT05891821 · Immune Oncology Research Institute
2023-09-01 – 2029-09 · Lymphoma
What this study did
NCT05608044 · Agenus Inc.
2022-11-30 – 2029-09 · Metastatic Colorectal Cancer
What this study did
NCT07551596 · National Cancer Institute (NCI)
2027-05-25 – 2029-08-28 · Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
What this study did
NCT07516366 · National Cancer Institute (NCI)
2027-05-17 – 2028-12-31 · Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
NCT07595874 · City of Hope Medical Center
2026-07-01 – 2028-12-16 · Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
What this study did
NCT07550088 · Darren Sigal, MD
2026-06-10 – 2028-12 · Colorectal Cancer Metastatic
What this study did
NCT06268015 · Nicholas DeVito, MD
2024-11-18 – 2028-07 · Colorectal Cancer
What this study did
NCT05845450 · Gruppo Oncologico del Nord-Ovest
2023-05-11 – 2028-05 · Colorectal Cancer, Resectable Colorectal Carcinoma
What this study did
NCT06843434 · Memorial Sloan Kettering Cancer Center
2025-02-20 – 2028-02-20 · Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal Adenocarcinoma
What this study did
NCT04028063 · University of Colorado, Denver
2020-01-28 – 2027-12-31 · Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma
What this study did
NCT06300463 · Weill Medical College of Cornell University
2024-03-26 – 2027-12 · Colorectal Cancer Metastatic, Liver Metastases, Colorectal Cancer
What this study did
NCT05928806 · Michael B. Atkins, MD
2023-09-25 – 2027-11-10 · Advanced Renal Cell Carcinoma
What this study did
NCT06780787 · City of Hope Medical Center
2025-05-20 – 2027-11-05 · Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
What this study did
NCT06251973 · Memorial Sloan Kettering Cancer Center
2024-02-01 – 2027-08-01 · Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Cancer, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Carcinoma, Unresectable Esophageal Cancer, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06589440 · Stingray Therapeutics
2024-11-20 – 2027-07-31 · Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
What this study did
NCT05561491 · Targovax Oy
2024-01 – 2027-06 · Melanoma
What this study did
NCT06575725 · City of Hope Medical Center
2024-11-01 – 2027-01-28 · Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma, Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
What this study did
NCT05363709 · M.D. Anderson Cancer Center
2023-10-18 – 2026-05-04 · HPV, Oropharyngeal Cancer
What this study did
NCT05529316 · Agenus Inc.
2022-12-12 – 2026-04-27 · Advanced Melanoma
What this study did
NCT05638698 · University of Kansas Medical Center
2022-12-15 – 2025-12 · Pancreas Cancer
What this study did
NCT05571293 · Weill Medical College of Cornell University
2023-03-17 – 2024-11-14 · Colorectal Neoplasms
What this study did
NCT04430036 · The University of Texas Health Science Center at San Antonio
2020-10-14 – 2022-03-14 · Urinary Bladder Neoplasms
What this study did
NCT04607200 · Agenus Inc.
2021-02 – 2021-09-13 · Angiosarcoma
What this study did
Phase 1/2 (7)
Cervical Cancer
Other / comorbidity
NCT06782932 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2025-05-27 – 2028-12 · Pancreatic Cancer
What this study did
NCT06782555 · ImmunoGenesis
2025-01-08 – 2028-01 · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
What this study did
NCT05627635 · City of Hope Medical Center
2023-05-03 – 2027-06-16 · Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
What this study did
NCT05205330 · Rottapharm Biotech
2021-11-23 – 2027-06 · Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic GI Cancers, Gastric Cancer
What this study did
NCT05672316 · City of Hope Medical Center
2023-05-11 – 2026-12-01 · Advanced Colorectal Adenocarcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
What this study did
Phase 1 (11)
Cervical Cancer
NCT06095674 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2024-01 – 2026-01 · Cervical Cancer
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT06411691 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2024-11-04 – 2030-11-01 · Colorectal Cancer, Pancreatic Cancer
What this study did
NCT07193862 · Northwell Health
2025-12-10 – 2028-04-15 · Colorectal Cancer Metastatic
What this study did
NCT06336902 · University of Southern California
2025-01-15 – 2028-01-15 · Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
What this study did
NCT04943848 · Ann & Robert H Lurie Children's Hospital of Chicago
2022-01-10 – 2027-09 · Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
What this study did
NCT07128355 · Massachusetts General Hospital
2026-05-12 – 2027-09 · Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis
What this study did
NCT06076837 · HonorHealth Research Institute
2025-01-09 – 2025-12-22 · Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
What this study did
NCT05377528 · Agenus Inc.
2022-07-19 – 2024-12-23 · Advanced Solid Tumor
What this study did
NCT05930951 · Groupe Oncologie Radiotherapie Tete et Cou
2023-11-29 – 2024-10-09 · Adenoid Cystic Carcinoma of the Head and Neck
What this study did
NCT04156100 · Agenus Inc.
2019-12-10 – 2021-09-29 · Advanced Solid Tumor
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, 22 of them ahead of this one.

This drug's own stage for Cervical Cancer: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Balstilimab: this drugPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)ApprovedAntibody–drug conjugateTissue Factor (TF)Partial signal
NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7)
NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sutantatug EnvedotinPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
ALE.P02
Phase 1/2(overall)
Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(29 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Balstilimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1/2Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer …Active not recruiting
Est. primary completion 2026-12 · NCT05205330 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer Metastatic, Liver Metastases, Colorectal CancerRecruiting
Est. primary completion 2026-12 · NCT06300463 · CT.gov ↗
What to watch
2027 (11)
January 2027 (2)
Phase 1Non-MSI-H or pMMR Colorectal Cancer With Liver MetastasisRecruiting
Est. primary completion 2027-01-01 · NCT07128355 · CT.gov ↗
What to watch
Phase 1Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8Recruiting
Est. primary completion 2027-01-15 · NCT06336902 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue SarcomaActive not recruiting
Est. primary completion 2027-04-07 · NCT04028063 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Colorectal Cancer, Resectable Colorectal CarcinomaRecruiting
Est. primary completion 2027-05 · NCT05845450 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Early Rectal Cancer, Stage I Rectal Cancer, Microsatellite Stable Rectal CarcinomaRecruiting
Est. primary completion 2027-06-01 · NCT07735624 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma …Active not recruiting
Est. primary completion 2027-06-16 · NCT05627635 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)Recruiting
Est. primary completion 2027-07-31 · NCT06589440 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer …Active not recruiting
Est. primary completion 2027-08-01 · NCT06251973 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2027-09 · NCT05608044 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic CancerActive not recruiting
Est. primary completion 2027-10 · NCT06782555 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8Recruiting
Est. primary completion 2027-11-05 · NCT06780787 · CT.gov ↗
What to watch
2028 (8)
February 2028 (1)
Phase 2Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal AdenocarcinomaRecruiting
Est. primary completion 2028-02-20 · NCT06843434 · CT.gov ↗
What to watch
April 2028 (1)
Phase 1Colorectal Cancer MetastaticRecruiting
Est. primary completion 2028-04-15 · NCT07193862 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Gastric Cancer, MSI-H, Metastatic Cancer, Advanced CancerRecruiting
Est. primary completion 2028-05-15 · NCT06346197 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2028-07 · NCT06268015 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Colorectal Cancer MetastaticRecruiting
Est. primary completion 2028-09 · NCT07550088 · CT.gov ↗
What to watch
December 2028 (3)
Phase 1/2Pancreatic CancerRecruiting
Est. primary completion 2028-12 · NCT06782932 · CT.gov ↗
What to watch
Phase 2Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma, Stage IIB Colon Cancer AJCC v8 …Recruiting
Est. primary completion 2028-12-16 · NCT07595874 · CT.gov ↗
What to watch
Phase 2Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8Recruiting
Est. primary completion 2028-12-31 · NCT07516366 · CT.gov ↗
What to watch
2029 (4)
January 2029 (1)
Phase 2/3Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid TumorsRecruiting
Est. primary completion 2029-01-29 · NCT06279130 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8Recruiting
Est. primary completion 2029-08-28 · NCT07551596 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2LymphomaRecruiting
Est. primary completion 2029-09 · NCT05891821 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1Colorectal Cancer, Pancreatic CancerRecruiting
Est. primary completion 2029-11-01 · NCT06411691 · CT.gov ↗
What to watch
2030 (3)
April 2030 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-04 · NCT06322108 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic CancerRecruiting
Est. primary completion 2030-08-01 · NCT06843551 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Colorectal Cancer, Rectal CancerRecruiting
Est. primary completion 2030-11 · NCT07227636 · CT.gov ↗
What to watch
2031 (1)
July 2031 (1)
Phase 2Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma MultiformeActive not recruiting
Est. primary completion 2031-07-31 · NCT05864534 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2026ApprovalArmenia grants the first marketing authorizations for botensilimab and balstilimab
AM, Ministry of Health of Armenia · Agenus Inc. · Source ↗